Genmab — Maj 2020
-
NEWS ???? @US_FDA clears the first CRISPR-edited iPSC-derived therapy, FT538, for clinical investigation in combination with daratumumab for the treatment of multiple #myeloma. Read more on the @MM_Hub
️ loom.ly/m5AMEvw #mmsm https://twitter.com/mm_hub/status/1265326446572118024?s=21 -
Jo fra 20.05.20
så jeg efterfølgende -
you local Dara-hero Plesner co-author in this new article iin Nature Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab https://www.nature.com/articles/s41375-020-0855-4
-
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS) https://www.globenewswire.com/news-release/2020/05/27/2039066/0/en/Novartis-announces-new-late-breaking-ofatumumab-data-at-EAN-demonstrating-robust-efficacy-and-safety-in-the-treatment-of-relapsing-forms-of-multiple-sclerosis-RMS.html
-
-
Tak GB.
-
Biotech catalyst calendars and drug pipelines • BioPharmCatalyst
Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more
BioPharmCatalyst (www.biopharmcatalyst.com)
-
UPDATE 1-Roche, Novartis highlight intensifying rivalry in eye disease, MS https://www.reuters.com/article/roche-lucentis-port/update-1-roche-novartis-highlight-intensifying-rivalry-in-eye-disease-ms-idUSL8N2D90NH
. Godt jeg besindede mig og lod være. 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind